shr-1501
Recombinant proteinexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2019 (NCT03995472)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-15AGONIST
IL15 agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068589 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07073534 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2025 | Hengrui Therapeutics, Inc. |
| NCT06588179 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2024 | Fudan University |
| NCT05410730 | Phase 1/Phase 2 (Phase 2) | Nov 23, 2022 | Hengrui Therapeutics, Inc. |
| NCT04025957 | Phase 1 | Sep 30, 2019 | Hengrui Therapeutics, Inc. |
| NCT03995472 | Phase 1 | Aug 31, 2019 | Hengrui Therapeutics, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2019 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1